StockData
argenx SE logo

argenx SE (ARGX) income statement

ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$941.25−6.27 (-0.66%)

Close on Nov 18, 2026Market cap –P/E 48.1Yield –

argenx SE income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
5.12
Debt to equity
–
Debt to assets
–
Cash to current liabilities
227.6%

Valuation

P/E ratio
48.1
Price to sales
–
Price to book
–
Dividend yield
–

See a number that looks wrong?